FDG-PET and PET/CT in breast cancer staging

Breast Care

Volumn 2, Issue 6, 2007, Pages 372-377

  Avril, Norbert ^a,b,c   Mather, Stephen J ^a,b   Roylance, Rebecca ^a,b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; F 18 FDG; Follow up; Imaging; PET CT; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADVANCED CANCER; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; GLUCOSE METABOLISM; HUMAN; INTERMETHOD COMPARISON; LUNG METASTASIS; LYMPH NODE METASTASIS; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

EID: 38549089105     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000112224     Document Type: Review

References (32)

1. Rohren EM, Turkington TG, Coleman RE: Clinical applications of PET in oncology. Radiology 2004;231:305-332.
2. Townsend DW, Carney JP, Yap JT, Hall NC: PET/CT today and tomorrow. J Nucl Med 2004;45:4S-14S.
3. Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R: A combined PET/CT scanner for clinical oncology. J Nucl Med 2000;41:1369-1379.
4. Weber WA, Schwaiger M, Avril N: Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 2000;27:683-687.
5. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, Bender HG, Mueller-Gaertner HW: Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226-230.
6. Zasadny KR, Wahl RL: Standardized uptake values of normal tissues at PET with 2-[fluorine- 18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993;189:847-850.
7. Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, Ferris RL, Avril N: Posttreatment assessment of response using FDGPET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006;65:1315-1322.
8. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD: Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571-578.
9. Short S, Hoskin P, Wong W: Ovulation and increased FDG uptake on PET: potential for a false-positive result. Clin Nucl Med 2005;30:707.
10. Stahl A, Weber WA, Avril N, Schwaiger M: Effect of N-butylscopolamine on intestinal uptake of fluorine-18-fluorodeoxyglucose in PET imaging of the abdomen. Nuklearmedizin 2000;39:241-245.
11. Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, Biersack HJ: Value of F-18 fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997;17:1687-1692.
12. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK: Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431-435.
13. Dose J, Bleckmann C, Bachmann S, Bohuslavizki KH, Berger J, Jenicke L, Habermann CR, Janicke F: Comparison of fluorodeoxyglucose positron emission tomography and 'conventional diagnostic procedures' for the detection of distant metastases in breast cancer patients. Nucl Med Commun 2002;23:857-864.
14. Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P: F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003;38:250-256.
15. Siggelkow W, Zimny M, Faridi A, Petzold K, Buell U, Rath W: The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 2003;23:1859-1867.
16. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, Lindsley S, Austin-Seymour M, Livingston R: Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183:479-486.
17. Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S: A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 2006;50:61-67.
18. Isasi CR, Moadel RM, Blaufox MD: A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005;90:105-112.
19. Van der Hoeven JJ, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D, Meijer S, van der Wall E, Buter J, Pinedo HM, Teule GJ, Lammertsma AA: 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22:1253-1259.
20. Port ER, Yeung H, Gonen M, Liberman L, Caravelli J, Borgen P, Larson S: 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol 2006;13:677-684.
21. Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, Cortese AA, Hayes CE, Moe RE: Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210:807-814.
22. Ahmad A, Barrington S, Maisey M, Rubens RD: Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999;79:478-482.
23. Veit-Haibach P, Antoch G, Beyer T, Stergar H, Schleucher R, Hauth EA, Bockisch A: FDGPET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy. Br J Radiol 2007.
24. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL: Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33:254-262.
25. Piperkova E, Raphael B, Altinyay ME, Castellon I, Libes R, Sandella N, Heiba S, Abdel-Dayem H: Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management. Clin Nucl Med 2007;32:429-434.
26. Radan L, Ben-Haim S, Bar-Shalom R, Guralnik L, Israel O: The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006;107:2545-2551.
27. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratib O, Phelps ME, Czernin J: Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005;7:369-376.
28. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I: Detection of bone metastases in breast cancer by F-18 FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-3379.
29. Nakai T, Okuyama C, Kubota T, Yamada K, Ushijima Y, Taniike K, Suzuki T, Nishimura T: Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005;32:1253-1258.
30. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Yasuda S, Shohtsu A: Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99 Tcm-MDP bone scintigraphy. Nucl Med Commun 2001;22:875-879.
31. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC: Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 2002;128:325-328.
32. Du Y, Cullum I, Illidge TM, Ell PJ: Fusion of metabolic function and morphology: sequential [18F] fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007.